CDK4 and hepatocellular carcinoma: Indeed, combined Cdk4 and DHODH inhibition appeared to be synergistic—in the presence of palbociclib, HCC cells were exquisitely sensitive to BAY2402234 (at doses of 1 nM or less, Fig. 7, C).